After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, ...
The author highlights the real-life impacts on the residents of Knoxville and East Tennessee from Trump administration cuts to the NIH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback